



SALL4 – (Klon 6E3, Maus) Tumorstammzell- und Keimzelltumormarker

- Anwendungsgebiete: **Gynäko-, Uro-, Hämato-, Gastroenteropathologie**
- onkofetales Protein, **Stammzell-** und **Tumorstammzellmarker** (Schlüsselfaktor für Pluripotenz und Selbsterneuerung von embryonalen u. hämatopoetischen Stammzellen)
- zentraler Regulator für Überleben und Apoptose leukämischer Zellen (u.a. AML, MDS)
- mögliches therapeutisches Ziel bei **AML** (SALL4/HDAC/PTEN Pathway)¹³, **Blastenkrise der CML**¹⁴ und **hepatozellulärem Karzinom (HCC)**^{7,8}
- exprimiert in einer Untergruppe solider Tumoren (Mamma-, Ovarial-, Magenkarzinom, Wilms-Tumor, Keimzelltumoren, HCC)
- sensitivster Marker (~100%) für primär extragonadale **Keimzelltumoren** inkl. **Dottersacktumoren**¹⁻⁵
- unterscheidet ovariale Dottersacktumoren (SALL4+) von klarzelligen Tumoren (SALL4-)²
- unterscheidet HCC von Magenadenokarzinomen vom „hepatoiden Typ“¹⁰ (nukleäres Färbemuster, Prozentsatz gefärbter Tumorzellen)¹¹

Positive Tumoren:

- AML, Marker der CML-Blastenkrise, B-LBL, ALCL, MDS¹²⁻²⁰
- Keimzelltumoren (intratubuläre Keimzellneoplasie, Seminom, klassisch und spermatozytisch, Dysgerminom, Embryonales Karzinom, Dottersacktumor, ovariales Gonadoblastom); Teratom/Chorionkarzinom sind variabel.^{1,3,4}
- Maligne Rhabdoidtumoren (~80%)⁶
- Magenadenokarzinome vom „hepatoiden Typ“ (~15%)¹¹

	Seminom/ Dysgerminom	Embryonales Karzinom	Dottersack- tumor	Chorion- Karzinom	Reifes Teratom	Unreifes Teratom	Karzinoid
SALL4 385M-1	+	+	+	-	-	+/-	-
SOX-2 371R-1	-	+	-	-	+/-	+	-
Oct-4 309M-1	+	+	-	-	-	-	-
PLAP 321R-1	+	+	-/+	+/-	+/-	-	-
CD117 117R-1	+	-	-/+	-	-	+/-	-
CD30 130M-9	-	+	-	-	-	-	-
AFP 203A-1	-	-	+	-	+/-	-	-
beta-hCG 234A-1	-	-	-	+	-	+/-	-
hPL 266A-1	-	-	-	+	-	-	-
CK Cocktail 313M-1	+/-	+	+	+	+	-	+
D2-40 322M-1	+	-	-	-	-	-	-
Synaptophysin 336R-9	-	-	-	-	-	-	+
Glypican-3 261M-9	-	-	+	-	-	-	-

Antikörper	Klon	Spezies	Verdünnung	konzentriert			gebrauchsfertig/RTU	
				0,1 ml	0,5 ml	1,0 ml	1 ml	7 ml
AFP	polyklonal	Kaninchen	50-200	203A-14	203A-15	203A-16	203A-17	203A-18
beta-hCG	polyklonal	Kaninchen	50-250	234A-14	234A-15	234A-16	234A-17	234A-18
CD30	Ber-H2	Maus	50-200	130M-94	130M-95	130M-96	130M-97	130M-98
CD117	YR145	Kaninchen	25-100	117R-14	117R-15	117R-16	117R-17	117R-18
CK Cocktail*	AE1/AE3	Maus	100-500	313M-14	313M-15	313M-16	313M-17	313M-18
D2-40	D2-40	Maus	20-100	322M-14	322M-15	322M-16	322M-17	322M-18
Glypican-3	1G12	Maus	100-500	261M-95	261M-96	261M-97	261M-98	261M-99
hPL	polyklonal	Kaninchen	50-200	266A-14	266A-15	266A-16	266A-17	266A-18
Nestin	10C2	Maus	25-100	388M-14	388M-15	388M-16	388M-17	388M-18
Oct-4	MRQ-10	Maus	50-200	309M-14	309M-15	309M-16	309M-17	309M-18
PLAP	SP15	Kaninchen	500-1.000	321R-14	321R-15	321R-16	321R-17	321R-18
SALL4	6E3	Maus	100-500	385M-14	385M-15	385M-16	385M-17	385M-18
Sox2	SP76	Kaninchen	50-200	371R-14	371R-15	371R-16	371R-17	371R-18
Synaptophysin	MRQ-40	Kaninchen	100-500	336R-94	336R-95	336R-96	336R-97	336R-98

* CK Cocktail ist außerdem noch gebrauchsfertig als 15 ml (313M-19) und 25 ml (313M-10) erhältlich.

Referenzen SALL4

Keimzelltumoren

1. Liu A, *et al.* Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. *Am J Surg Pathol* 2010; 34: 697-706.
2. Cao D, *et al.* SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. *Am J Surg Pathol* 2009; 33: 894-904.
3. Cao D, *et al.* SALL4 is a novel diagnostic marker for testicular germ cell tumors. *Am J Surg Pathol* 2009; 33: 1065-1077.
4. Cao D, *et al.* SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. *Cancer* 2009; 115: 2640-2651.
5. Wang F, *et al.* Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. *Am J Surg Pathol* 2009; 33: 1529-1539.

Rhabdoid-Tumoren

6. Venneti S, *et al.* Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins. *Am J Surg Pathol* 2011; 35: 1463-1472.

Gastroenteropathologie

7. Marquardt JU, Thorgeirsson SS. Sall4 in "stemness"-driven hepatocarcinogenesis. *N Engl J Med* 2013; 368(24): 2316-2318.
8. Yong KJ, *et al.* Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. *N Engl J Med* 2013; 368(24): 2266-2276.
9. Oikawa T, *et al.* Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. *Hepatology* 2013; 57(4): 1469-1483.
10. Gonzalez-Roibon N, *et al.* Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. *Hum Pathol* 2013; 44(7): 1293-1299.
11. Ushiku T, *et al.* SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. *Am J Surg Pathol* 2010; 34: 533-540.

Hämatopathologie (AML, CML-Blastenkrise, MDS, B-LBL, ALCL)

12. Cui W, *et al.* Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. *Mod Pathol* 2006; 19: 1585-1592.
13. Gao C, *et al.* Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. *Blood* 2013; 121: 1413-1421.
14. Lu J, *et al.* Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. *Leukemia* 2011; 25: 1211-1213.
15. Aguila JR, *et al.* SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. *Blood* 2011; 118: 576-585.
16. Wang P, *et al.* The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma. *Cell Signal* 2012; 24: 1955-1963.
17. Yang J, *et al.* Role of SALL4 in hematopoiesis. *Curr Opin Hematol* 2012; 19: 287-291.
18. Gao C, *et al.* The role of stem cell factor SALL4 in leukemogenesis. *Crit Rev Oncog* 2011; 16: 117-127.
19. Ma Y, *et al.* SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. *Blood* 2006; 108(8): 2726-2735.
20. Shuai X, *et al.* Overexpression of the novel oncogene SALL4 and activation of the Wnt/ β -catenin pathway in myelodysplastic syndromes. *Cancer Genet Cytogenet* 2009; 194(2): 119-124.